ARDELYX, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
ARDELYX, INC. (ARDX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-06
- ARDELYX, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- ARDELYX, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- ARDELYX, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- ARDELYX, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $482.00K, a 50.16% increase year-over-year.
- ARDELYX, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $4.36M, a 331.88% increase from fiscal 2024.
- ARDELYX, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $1.01M, a 197.94% increase from fiscal 2023.
- ARDELYX, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $339.00K.
- ARDELYX, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $482.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-04-30 | $0.00 derived: sum of 2 quarters · filed 2026-04-30 | $482.00K derived: sum of 3 quarters · filed 2026-04-30 | $2.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $482.00K derived: sum of 2 quarters · filed 2026-02-19 | $2.15M derived: sum of 3 quarters · filed 2026-08-06 | $4.36M 10-K · filed 2026-02-19 |
| 2025-09-30 | $482.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $2.15M derived: sum of 2 quarters · filed 2026-08-06 | $4.36M 10-Q · filed 2025-10-30 | $4.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.88M 10-Q · filed 2026-08-06 | $3.88M derived: sum of 3 quarters · filed 2026-08-06 | $4.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.21M 10-Q · filed 2026-04-30 | $2.21M derived: sum of 2 quarters · filed 2026-04-30 | $2.53M derived: sum of 3 quarters · filed 2026-04-30 | $3.22M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $321.00K derived: sum of 2 quarters · filed 2026-02-19 | $1.01M derived: sum of 3 quarters · filed 2026-02-19 | $1.01M 10-K · filed 2026-02-19 |
| 2024-09-30 | $321.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $1.01M derived: sum of 2 quarters · filed 2025-10-30 | $1.01M 10-Q · filed 2025-10-30 | $1.01M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $689.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $689.00K 10-Q · filed 2025-08-04 | $689.00K derived: sum of 3 quarters · filed 2026-02-19 | $1.03M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-01 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $339.00K derived: sum of 3 quarters · filed 2026-02-19 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $339.00K derived: sum of 2 quarters · filed 2026-02-19 | $339.00K 10-K · filed 2026-02-19 | |
| 2023-09-30 | $339.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $339.00K 10-Q · filed 2024-10-31 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-01 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $0.00 derived: sum of 2 quarters · filed 2025-02-20 | $0.00 derived: sum of 3 quarters · filed 2025-02-20 | $0.00 10-K · filed 2025-02-20 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $0.00 derived: sum of 2 quarters · filed 2023-10-31 | $0.00 10-Q · filed 2023-10-31 | -$12.78M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | -$12.78M derived: sum of 3 quarters · filed 2024-02-22 | -$12.78M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 | -$12.78M derived: sum of 2 quarters · filed 2024-02-22 | -$12.78M derived: sum of 3 quarters · filed 2024-02-22 | $1.15M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$12.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$12.78M derived: sum of 2 quarters · filed 2024-02-22 | $1.15M derived: sum of 3 quarters · filed 2024-02-22 | $1.60M 10-K · filed 2024-02-22 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $13.93M derived: sum of 2 quarters · filed 2022-11-03 | $14.38M 10-Q · filed 2022-11-03 | $14.83M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $13.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $14.38M 10-Q · filed 2022-08-04 | $14.83M derived: sum of 3 quarters · filed 2023-03-02 | $14.83M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $450.00K 10-Q · filed 2022-05-05 | $900.00K derived: sum of 2 quarters · filed 2023-03-02 | $900.00K derived: sum of 3 quarters · filed 2023-03-02 | -$4.91M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | $450.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $450.00K derived: sum of 2 quarters · filed 2023-03-02 | -$5.36M derived: sum of 3 quarters · filed 2023-03-02 | $450.00K 10-K · filed 2023-03-02 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$5.81M derived: sum of 2 quarters · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | $0.00 derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$5.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $0.00 10-Q · filed 2021-08-13 | $0.00 derived: sum of 3 quarters · filed 2022-02-28 | $0.00 derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $5.81M 10-Q · filed 2021-05-06 | $5.81M derived: sum of 2 quarters · filed 2022-02-28 | $5.81M derived: sum of 3 quarters · filed 2022-02-28 | $5.81M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $0.00 derived: sum of 3 quarters · filed 2022-02-28 | $5.81M 10-K · filed 2022-02-28 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $5.81M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $5.81M 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $5.81M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |